Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Maté Ongenaert (Mechelen, Belgium), Maté Ongenaert, Sonia Dupont, Roland Blanqué, Reginald Brys, Ellen van der Aar, Bertrand Heckmann. Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF. Eur Respir J 2016; 48: Suppl. 60, 4540

Member's Comments

No comment yet.

Related content which might interest you: Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Effect of pirfenidone on IPF progression Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Novel lung function tests in patients with interstitial lung disease (ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis Source: International Congress 2016 – Connective tissue disorders Year: 2016 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 "Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease" Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 A role of Foxc2 gene in mice with bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Biomarkers for interstitial lung disease Source: International Congress 2016 – ME1 Biomarkers for interstitial lung disease Year: 2016 KCa3.1 channel inhibition prevents fibrotic responses in a human lung explant model Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 IGFBP-2 a new interesting target in IPF Source: International Congress 2016 – ILD pathogenesis Year: 2016 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Difference in the dynamic state between SP-A and SP-D in the IPF lung Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013